Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SOS1 | Q07889 | 2/20 | 0.48 |
| ▸ | RAPGEF4 | Q8WZA2 | 2/20 | 0.41 |
| ▸ | EPAS1 | Q99814 | 2/20 | 0.36 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.33 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | TDO2 | P48775 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | AR | P10275 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.31 |
| ▸ | CTSV | O60911 | 1/20 | 0.30 |
| ▸ | PLAT | P00750 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3932395 | 0.81 | MEN1 (0.40) | RAB9AMEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL5542017 | 0.81 | RAPGEF4 (0.49) | RAPGEF4RAB9AMEN1ALDH1A1AR | |
| SCHEMBL12467721 | 0.80 | HSD17B10 (0.44) | RAB9AMEN1ALDH1A1ARMAPT | |
| SCHEMBL392912 | 0.80 | RAPGEF4 (0.54) | SOS1RAPGEF4EPAS1GRM4HDAC3 | |
| SCHEMBL1118796 | 0.76 | HSD17B10 (0.60) | SOS1RAPGEF4EPAS1RAB9AMEN1 | |
| SCHEMBL5542981 | 0.74 | SOS1 (0.53) | SOS1RAPGEF4GRM4TDO2RAB9A | |
| SCHEMBL5541842 | 0.73 | RAPGEF4 (0.41) | RAPGEF4EPAS1GRM4RAB9AMEN1 | |
| SCHEMBL11659508 | 0.73 | RAPGEF4 (0.46) | RAPGEF4GRM4RAB9AMEN1ALDH1A1 | |
| SCHEMBL15152175 | 0.73 | SOS1 (0.53) | SOS1RAPGEF4EPAS1MEN1ALDH1A1 | |
| SCHEMBL5535505 | 0.73 | MEN1 (0.45) | SOS1RAPGEF4RAB9AMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102532162-B | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMA CO LTD | 2015-05-27 | — | — | CN | disclosed |
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | SOS1 768/4885RAPGEF4 4025/4885EPAS1 4415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.